Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.206 EUR
−4.61 M EUR
4.54 M EUR
21.40 M
About BIORETEC OY
Sector
Industry
CEO
Sarah Frances van Hellenberg Hubar-Fisher
Website
Headquarters
Tampere
Founded
1998
ISIN
FI4000590955
FIGI
BBG01V8VPRW1
Bioretec Ltd. develops bioabsorbable and bioresorbable implants for pediatric and adult orthopaedics. It specializes in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The company's products include bioabsorbable nails, pins, and screws as well as bioresorbable magnesium implants. Bioretec was founded in 1998 and is headquartered in Tampere, Finland.
Related stocks
Frequently Asked Questions
The current price of BRETECN0125 is 1.760 EUR — it has increased by 2.33% in the past 24 hours. Watch BIORETEC OY NEW SHARE stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OMXHEX exchange BIORETEC OY NEW SHARE stocks are traded under the ticker BRETECN0125.
BRETECN0125 stock has risen by 4.76% compared to the previous week, the month change is a 4.76% rise, over the last year BIORETEC OY NEW SHARE has showed a 4.76% increase.
BRETECN0125 stock is 3.45% volatile and has beta coefficient of 0.99. Track BIORETEC OY NEW SHARE stock price on the chart and check out the list of the most volatile stocks — is BIORETEC OY NEW SHARE there?
Today BIORETEC OY NEW SHARE has the market capitalization of 57.72 M, it has decreased by −12.11% over the last week.
Yes, you can track BIORETEC OY NEW SHARE financials in yearly and quarterly reports right on TradingView.
BIORETEC OY NEW SHARE is going to release the next earnings report on Aug 14, 2025. Keep track of upcoming events with our Earnings Calendar.
BRETECN0125 earnings for the last half-year are −0.10 EUR per share, whereas the estimation was −0.63 EUR, resulting in a 84.85% surprise. The estimated earnings for the next half-year are −0.06 EUR per share. See more details about BIORETEC OY NEW SHARE earnings.
BIORETEC OY NEW SHARE revenue for the last half-year amounts to 2.48 M EUR, despite the estimated figure of 3.20 M EUR. In the next half-year revenue is expected to reach 4.00 M EUR.
BRETECN0125 net income for the last half-year is −2.73 M EUR, while the previous report showed −1.88 M EUR of net income which accounts for −44.90% change. Track more BIORETEC OY NEW SHARE financial stats to get the full picture.
No, BRETECN0125 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 14, 2025, the company has 47 employees. See our rating of the largest employees — is BIORETEC OY NEW SHARE on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIORETEC OY NEW SHARE EBITDA is −4.05 M EUR, and current EBITDA margin is −89.21%. See more stats in BIORETEC OY NEW SHARE financial statements.
Like other stocks, BRETECN0125 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIORETEC OY NEW SHARE stock right from TradingView charts — choose your broker and connect to your account.